Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Absence of somatostatin receptor type 2 A mutations and gip oncogene in pituitary somatotroph adenomas
Autore:
Petersenn, S; Heyens, M; Ludecke, DK; Beil, FU; Schulte, HM;
Indirizzi:
Univ Hamburg, IHF, Inst Hormone & Fertil Res, D-22529 Hamburg, Germany Univ Hamburg Hamburg Germany D-22529 ertil Res, D-22529 Hamburg, Germany Univ Hamburg, Hosp Eppendorf, Dept Neurosurg, D-20246 Hamburg, Germany Univ Hamburg Hamburg Germany D-20246 Neurosurg, D-20246 Hamburg, Germany Univ Hamburg, Hosp Eppendorf, Dept Med, D-20246 Hamburg, Germany Univ Hamburg Hamburg Germany D-20246 Dept Med, D-20246 Hamburg, Germany
Titolo Testata:
CLINICAL ENDOCRINOLOGY
fascicolo: 1, volume: 52, anno: 2000,
pagine: 35 - 42
SICI:
0300-0664(200001)52:1<35:AOSRT2>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACROMEGALIC PATIENTS; ADENYLYL CYCLASE; BIOCHEMICAL CHARACTERISTICS; SECRETING ADENOMAS; TUMORS; EXPRESSION; CELLS; PROTEIN; SUBTYPES; ALPHA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Petersenn, S Univ Hamburg, IHF, Inst Hormone & Fertil Res, Grandweg 64, D-22529 Hamburg, Germany Univ Hamburg Grandweg 64 Hamburg Germany D-22529 rg, Germany
Citazione:
S. Petersenn et al., "Absence of somatostatin receptor type 2 A mutations and gip oncogene in pituitary somatotroph adenomas", CLIN ENDOCR, 52(1), 2000, pp. 35-42

Abstract

OBJECTIVE Somatostatin, acting via specific receptors in the anterior pituitary, tonically inhibits pituitary growth hormone secretion and somatotroph proliferation. Reduction of growth hormone secretion and tumour regression in GH-secreting pituitary adenomas treated with long-acting somatostatin analogues varies widely. In 30-40% of these tumours dominant somatic mutations of the G(s)alpha gene (gsp) have been demonstrated leading to constitutive adenylyl cyclase induction. A relationship between somatostatin sensitivity and tumour pathogenesis in some tumours has been suggested. Changes inthe function of the somatostatin receptor or intracellular signal elementsmay be of relevance. Somatostatin receptor type 2 A (sst2A) and G(i2) are proposed to mediate selectively the inhibition of GH release in the somatotroph. We therefore investigated the presence of sst2A mutations and gip oncogene in somatotrophic pituitary adenomas. DESIGN Tumour samples from 15 patients with pituitary somatotroph adenomaswere obtained. RNA was isolated and used for reverse transcription and subsequent polymerase chain reaction. All samples were screened for the presence of sst2A mutations and of the gip oncogene by SSCP analysis and sequencing. For comparison, the gsp oncogene was examined. The relationship betweenclinical data and molecular analysis results was investigated. RESULTS Seven of the tumours harboured a gsp mutation. No mutations affecting the sst2A protein were found in any of the tumours analysed. Furthermore, gip oncogene was absent in all tumours. CONCLUSION Mutations of the somatostatin receptor type 2 A and the gip oncogene are unlikely to be involved in the pathogenesis of acromegaly.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/11/20 alle ore 10:22:10